Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom ...
Zacks Investment Research on MSN
Dexcom reports positive CONNECT data for non-insulin diabetes
DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of ...
Medical Device Network on MSN
ADA26: Dexcom’s G7 CGM helps TD2 diabetics not on insulin manage glucose levels
Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...
Dexcom (Nasdaq:DXCM) today announced findings from a study demonstrating the benefits of its G7 CGM in type 2 diabetes.
By Sneha S K June 6 (Reuters) - Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not using insulin, ...
New study results could lead to better insurance coverage of the devices for people who don’t take insulin, a researcher said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results